Tharick A. Pascoal

Research interests

Publications

• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  JAMA Neurology · 2024 · https://doi.org/10.1001/jamaneurol.2023.5319

• Biomarker-based staging of Alzheimer disease: rationale and clinical applications

  Nature Reviews Neurology · 2024 · https://doi.org/10.1038/s41582-024-00942-2

• Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease

  Nature Medicine · 2023 · 10.1038/s41591-023-02380-x

• Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease

  Alzheimer s & Dementia · 2023 · 10.1002/alz.13026

• Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

  Nature Reviews Neurology · 2022 · 10.1038/s41582-022-00665-2

• Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

  EBioMedicine · 2022 · https://doi.org/10.1016/j.ebiom.2022.103836

• Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

  Nature Aging · 2022 · 10.1038/s43587-022-00204-0

• Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography

  JAMA Neurology · 2022 · 10.1001/jamaneurol.2022.4485

• Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease

  Molecular Psychiatry · 2022 · 10.1038/s41380-022-01716-2

• Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

  JAMA Neurology · 2021 · https://doi.org/10.1001/jamaneurol.2021.3671

• Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

  Acta Neuropathologica · 2021 · https://doi.org/10.1007/s00401-021-02275-6

• A multicentre validation study of the diagnostic value of plasma neurofilament light

  Nature Communications · 2021 · https://doi.org/10.1038/s41467-021-23620-z

• Microglial activation and tau propagate jointly across Braak stages

  Nature Medicine · 2021 · 10.1038/s41591-021-01456-w

• Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease

  Translational Psychiatry · 2021 · 10.1038/s41398-021-01349-z

• Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

  Clinical Chemistry and Laboratory Medicine (CCLM) · 2021 · 10.1515/cclm-2021-0651

• 18F-MK-6240 PET for early and late detection of neurofibrillary tangles

  Brain · 2020 · 10.1093/brain/awaa180

• Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals

  Alzheimer s & Dementia · 2020 · 10.1002/alz.12007

• Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

  Molecular Psychiatry · 2020 · 10.1038/s41380-020-00923-z

• Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

  The Lancet Neurology · 2020 · https://doi.org/10.1016/s1474-4422(20)30071-5

• Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β

  JAMA Neurology · 2019 · 10.1001/jamaneurol.2019.4421

• In vivo quantification of neurofibrillary tangles with [18F]MK-6240

  Alzheimer s Research & Therapy · 2018 · https://doi.org/10.1186/s13195-018-0402-y

• Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

  Alzheimer s Research & Therapy · 2017 · 10.1186/s13195-017-0253-y

• Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer’s disease

  Molecular Psychiatry · 2016 · 10.1038/mp.2016.37

Current projects

No projects listed.